About US
Contact us
-
US FDA approves Venclexta tablets to treat chronic lymphocytic leukaemiaThe US Food and Drug Administration (FDA) has approved a new drug Venclexta (venetoclax) to treat chronic lymphocytic leukaemia (CLL) in patients with a specific chromosomal abnormality. Designed to2016/4/14
-
Researchers suspect link between Zika virus and acute disseminated encephalomyelitisA new report presented at the American Academy of Neurology's 68th annual meeting suggests that the Zika virus may be responsible for the cause of acute disseminated encephalomyelitis (ADEM), an autoi2016/4/14
-
Valeant wins new 10-K deadline from creditors, but gives up dealmaking freedom in returnValeant Pharmaceuticals ($VRX) snagged creditor approval to extend its annual report filing deadline into May in return for some concessions on its debt terms. The company had been in danger of defaul2016/4/13
-
Drug industry lashes out at Massachusetts drug price transparency effortThe Boston and Cambridge area may be one of the top biotech research hubs in the world. But that hasn't buffered it from the anger of some state lawmakers over the costs of some drugs they say are eat2016/4/13
-
Sun Pharma obtains US FDA approval for BromSiteThe US Food and Drug Administration (FDA) has given its approval for Sun Pharma's eye inflammation drug BromSite (bromfenac ophthalmic solution). BromSite is the first non-steroidal anti-inflammatory2016/4/12
-
Deals this week: Cutis Pharma, Sorrento Therapeutics, Yinnan Baiyao GroupCutis Pharmahas entered a joint development agreement with Dr Reddy's Laboratories for the supply of active pharmaceutical ingredients (API). The partnership enables Cutis Pharma to develop worldwide2016/4/12
-
Pfizer investors stand with CEO Read even though he is 0 for 2 on megamergersRead given credit for remaking Pfizer and investors don't blame him for miss on Allergan Pfizer ($PFE) CEOIan Readwalked away from its $160 billion merger with Allergan ($AGN) this week after U.S.Tre2016/4/11
-
Novo makes inroads in Japan with long-acting insulin TresibaNovo Nordisk ($NVO) didn't know how fraught its path would be withTresibain 2012, when it won Japanese approval for the drug. The company built up Tresiba in the country even as approval in the U.S. w2016/4/11
-
GSK Consumer Healthcare inaugurates new facility in USGSK Consumer Healthcare has inaugurated a new facility in Warren, New Jersey, US, which will employ nearly 900 people. The facility has been opened as part of a joint venture between GSK and Novartis2016/4/8
-
Novo Nordisk to Attend BioProcess International European SummitNovo Nordisk will be attending the BioProcess International European Summit from 12-13 April in Vienna, Austria. If visitors are looking to optimise cell density and viability, insulin might play an2016/4/8